Sage Therapeutics and Biogen Announce SAGE-324 Phase 2 Placebo-Controlled KINETIC Study in Essential Tremor Met Primary Endpoint

Posted on April 20, 2021

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Apr. 12, 2021– Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) today reported topline results from the Phase 2 KINETIC Study evaluating SAGE-324 in the treatment of people with essential tremor (ET).

Categories: In the News

Leave a Reply

Your email address will not be published. Required fields are marked *